Sickle Cell Clinic Expansion and Enhancement Program Competitive

The Michigan Department of Health and Human Services (MDHHS), through its Bureau of Epidemiology and Population Health, has issued a competitive grant funding opportunity for the Sickle Cell Clinic Expansion and Enhancement Program (SCCEE) for fiscal year 2026. This initiative is supported by State General Funds and Medicaid and aims to improve health outcomes for individuals diagnosed with sickle cell disease (SCD) by expanding and enhancing access to quality, integrated care services across Michigan. The grant is designed to help bridge existing gaps in care for SCD patients, particularly adults, by enabling clinics to implement evidence-based and innovative service delivery models that are responsive to the needs of this population. The SCCEE grant is intended for organizations that are either hematology or hematology/oncology clinics or emergency departments operating under a Michigan hospital or medical school. These entities must be enrolled Michigan Medicaid providers and agree to accept patients from Medicaid, MI Child, Healthy Michigan Plan, and Children’s Special Health Care Services (CSHCS) programs. Eligible applicants include nonprofit 501(c)(3) organizations, public and private entities, and universities that meet the outlined criteria. The program will fund up to five awards, with each recipient eligible to receive between $60,000 and $80,000 during the initial funding period from April 1, 2026, to September 30, 2026. Applicants may address one, two, or all three of the following priority funding areas: improving access to quality, integrated care; increasing the use of disease-modifying therapies; and expanding acute care services for individuals with SCD. Project examples under these categories include the development of lifespan clinics, implementation of telehealth initiatives, enhancement of care coordination networks, establishment of infusion clinics and observational units, and the adoption of decision support tools and standardized clinical protocols. Proposals must clearly articulate their alignment with these funding priorities and demonstrate how they will incorporate human-centered design and best practices. While cost sharing or matching is not mandatory, it is encouraged and may take the form of cash or in-kind contributions. However, grant funds may not be used to supplant existing funding sources or support ineligible activities, such as research, building construction, or services already reimbursed through Medicaid or other insurers. Each project must adhere to all MDHHS requirements, including compliance with reporting guidelines, staff credentialing, and participation in evaluation and performance monitoring efforts. The application must be submitted through the EGrAMS portal by the authorized official of the applicant organization no later than January 27, 2026, at 3:00 p.m. EST. Applicants must register with EGrAMS, obtain a Unique Entity Identifier through SAM.gov, and complete a vendor registration with Michigan’s SIGMA system before submitting their applications. A pre-application webinar will be held on January 6, 2026, with a recording made available afterward. Additional technical assistance will be offered through noon on the deadline day. Proposals will be scored on a 100-point scale, with a minimum of 80 points required for funding consideration. Evaluation will focus on applicant qualifications, alignment with funding priorities, project design, work plan, outcome metrics, budget, and ability to serve Michigan’s SCD population. Award decisions will be announced via EGrAMS by March 13, 2026, and awarded projects must begin by April 1, 2026. Pending available funds and successful project performance, selected grantees may be eligible for non-competitive continuation funding through September 30, 2030.

Ensure alignment with one or more priority areas (access, therapies, acute care); address human-centered design and SCD population needs; follow EGrAMS registration deadlines carefully.